Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...

Around 10 million people globally live with the life-threatening virus HTLV-1. Yet it remains a poorly understood disease ...

Many at-risk Americans either do not know about PrEP or don't have access. Here's why raising awareness is key to ending the ...

Around 10 million people globally live with the life-threatening virus HTLV-1. Yet it remains a poorly understood disease that currently has no preventative treatments and no cure.

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for treatment in 133 countries.

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

A BREAKTHROUGH HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

The recommendation comes just weeks after the US Food and Drug Administration (FDA) approved the drug for use. Lenacapavir trials were conducted in Uganda and South Africa and demonstrated 100% ...